These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 23900136)
21. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer. Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. Lin SF; Lin JD; Hsueh C; Chou TC; Yeh CN; Chen MH; Wong RJ Oncotarget; 2017 Jun; 8(25):41294-41304. PubMed ID: 28476040 [TBL] [Abstract][Full Text] [Related]
23. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726 [TBL] [Abstract][Full Text] [Related]
24. Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. Wang Y; Liu H; Diao L; Potter A; Zhang J; Qiao Y; Wang J; Proia DA; Tailor R; Komaki R; Lin SH Clin Cancer Res; 2016 Dec; 22(23):5876-5886. PubMed ID: 27354472 [TBL] [Abstract][Full Text] [Related]
25. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412 [TBL] [Abstract][Full Text] [Related]
26. Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation. Patel K; Wen J; Magliocca K; Muller S; Liu Y; Chen ZG; Saba N; Diaz R Cancer Chemother Pharmacol; 2014 Nov; 74(5):1015-22. PubMed ID: 25205430 [TBL] [Abstract][Full Text] [Related]
27. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563 [TBL] [Abstract][Full Text] [Related]
28. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Lai CH; Park KS; Lee DH; Alberobello AT; Raffeld M; Pierobon M; Pin E; Petricoin Iii EF; Wang Y; Giaccone G Oncogene; 2014 Oct; 33(40):4867-76. PubMed ID: 24166505 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Schwock J; Pham NA; Cao MP; Hedley DW Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866 [TBL] [Abstract][Full Text] [Related]
30. Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling. Lee H; Saini N; Parris AB; Zhao M; Yang X Int J Oncol; 2017 Sep; 51(3):967-974. PubMed ID: 28713919 [TBL] [Abstract][Full Text] [Related]
31. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma. Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297 [TBL] [Abstract][Full Text] [Related]
32. UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib. Landmann H; Proia DA; He S; Ogawa LS; Kramer F; Beißbarth T; Grade M; Gaedcke J; Ghadimi M; Moll U; Dobbelstein M Cell Death Dis; 2014 Sep; 5(9):e1411. PubMed ID: 25210794 [TBL] [Abstract][Full Text] [Related]
33. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer. Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685 [TBL] [Abstract][Full Text] [Related]
34. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer. Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263 [TBL] [Abstract][Full Text] [Related]
35. Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel. Liu X; Gao Y; Shen J; Yang W; Choy E; Mankin H; Hornicek FJ; Duan Z Mol Cancer Ther; 2016 Jul; 15(7):1691-701. PubMed ID: 27207777 [TBL] [Abstract][Full Text] [Related]
37. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis. Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781 [TBL] [Abstract][Full Text] [Related]
38. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Lock RB; Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA Pediatr Blood Cancer; 2013 Jul; 60(7):E42-5. PubMed ID: 23303741 [TBL] [Abstract][Full Text] [Related]
39. HSP90 inhibition downregulates DNA replication and repair genes via E2F1 repression. Liu H; Lu Z; Shi X; Liu L; Zhang P; Golemis EA; Tu Z J Biol Chem; 2021 Aug; 297(2):100996. PubMed ID: 34302809 [TBL] [Abstract][Full Text] [Related]
40. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Yang H; Mao W; Rodriguez-Aguayo C; Mangala LS; Bartholomeusz G; Iles LR; Jennings NB; Ahmed AA; Sood AK; Lopez-Berestein G; Lu Z; Bast RC Clin Cancer Res; 2018 Oct; 24(20):5072-5084. PubMed ID: 30084832 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]